Skip to menu Skip to content Skip to footer
News

Breakthrough may stop multiple sclerosis in its tracks

11 April 2016
The new drug is derived from Oldenlandia affinis, a traditional medicinal plant.
The new drug is derived from Oldenlandia affinis, a traditional medicinal plant.

An international research team has demonstrated that a new plant-derived drug can block the progression of multiple sclerosis (MS).

University of Queensland researcher Dr Christian Gruber said the breakthrough could be a step forward in preventing and treating MS and other autoimmune diseases.

“This is a really exciting discovery because it may offer a whole new quality of life for people with this debilitating disease,” he said.

The new drug is expected to be taken by mouth, in contrast to some current MS treatments where patients need to have frequent injections.  

MS is a chronic incurable condition marked by attacks that bring gradual deterioration in the patient’s health. About 23,000 people are affected in Australia and 2.5 million worldwide.

Dr Gruber said the new drug – named T20K – was extracted from a traditional medicinal plant, the Oldenlandia affinis.

The drug treatment had been successful in an animal model, and patent applications filed in several countries.

Decorative
“Phase one clinical trials could begin as early as 2018,” Dr Gruber said.

“Licences have been assigned to Cyxone, a company established last year to develop this new class of drugs for the treatment of autoimmune diseases.

“Cyxone’s immediate focus is on bringing T20K through the pre-clinical program required for delivering a safe, orally active drug.”

Dr Gruber said the new treatment arose from a synthesised plant peptide, a class of drugs known as cyclotides.

“Cyclotides are present in a range of common plants, and they show significant potential for the treatment of auto immune diseases,” he said.

“The T20K peptides exhibit extraordinary stability and chemical features that are ideally what you want in an oral drug candidate.”

The international research team demonstrated in an animal model that T20K stopped progression in the normal clinical symptoms of MS.

Dr Gruber, from UQ’s School of Biomedical Sciences, is also an international research fellow at the Center for Physiology and Pharmacology at the Medical University of Vienna.

He and his colleagues published their breakthrough research in PNAS.

Above: the flower of the Oldenlandia affinis. Photo: David Wilson

CONTACT: Dr Christian Gruber, c.gruber@uq.edu.au  +43 1 4016031390 (in Austria, forwards to international mobile); Avril Johnston-Craig, UQ Communications, a.johnstoncraig@uq.edu.au+61 7 365 1536, 0408 160 784.

Related articles

A doctor sits opposite his patient in a clinic
Opinion

Should you consent to your doctor using an AI scribe? Here’s what you should know.

There’s a period of time doctors refer to as “pyjama time” – the hours they spend late into the night writing notes on the patients they saw that day.
17 July 2025
A consumer type drone in flight.

How a drone delivering medicine might just save your life

Drones can deliver pizza, and maybe one day your online shopping. So why not use them to deliver urgent medicines or other emergency health-care supplies?
16 July 2025

Media contact

Subscribe to UQ News

Get the latest from our newsroom.